The Argatroban and Tissue-Type Plasminogen Activator Stroke Study Final Results of a Pilot Safety Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F12%3A%230000883" target="_blank" >RIV/00159816:_____/12:#0000883 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1161/STROKEAHA.111.625574" target="_blank" >http://dx.doi.org/10.1161/STROKEAHA.111.625574</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1161/STROKEAHA.111.625574" target="_blank" >10.1161/STROKEAHA.111.625574</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Argatroban and Tissue-Type Plasminogen Activator Stroke Study Final Results of a Pilot Safety Study

Popis výsledku v původním jazyce

Background and Purpose-Argatroban is a direct thrombin inhibitor that safely augments recanalization achieved by tissue-type plasminogen activator (tPA) in animal stroke models. The Argatroban tPA Stroke Study was an open-label, pilot safety study of tPAplus Argatroban in patients with ischemic stroke due to proximal intracranial occlusion. Methods-During standard-dose intravenous tPA, a 100-mu g/kg bolus of Argatroban and infusion for 48 hours was adjusted to a target partial thromboplastin time of 1.75 X baseline. The primary outcome was incidence of significant intracerebral hemorrhage defined as either symptomatic intracerebral hemorrhage or Parenchymal Hematoma Type 2. Recanalization was measured at 2 and 24 hours by transcranial Doppler or CT angiography. Results-Sixty-five patients were enrolled (45% men, mean age 63 +/- 14 years, median National Institutes of Health Stroke Scale=13). The median (interquartile range) time tPA to Argatroban bolus was 51 (38-60) minutes. Target a

Název v anglickém jazyce

The Argatroban and Tissue-Type Plasminogen Activator Stroke Study Final Results of a Pilot Safety Study

Popis výsledku anglicky

Background and Purpose-Argatroban is a direct thrombin inhibitor that safely augments recanalization achieved by tissue-type plasminogen activator (tPA) in animal stroke models. The Argatroban tPA Stroke Study was an open-label, pilot safety study of tPAplus Argatroban in patients with ischemic stroke due to proximal intracranial occlusion. Methods-During standard-dose intravenous tPA, a 100-mu g/kg bolus of Argatroban and infusion for 48 hours was adjusted to a target partial thromboplastin time of 1.75 X baseline. The primary outcome was incidence of significant intracerebral hemorrhage defined as either symptomatic intracerebral hemorrhage or Parenchymal Hematoma Type 2. Recanalization was measured at 2 and 24 hours by transcranial Doppler or CT angiography. Results-Sixty-five patients were enrolled (45% men, mean age 63 +/- 14 years, median National Institutes of Health Stroke Scale=13). The median (interquartile range) time tPA to Argatroban bolus was 51 (38-60) minutes. Target a

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

STROKE

ISSN

0039-2499

e-ISSN

—

Svazek periodika

43

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

770-775

Kód UT WoS článku

000300639400034

EID výsledku v databázi Scopus

—